Abstract: The invention provides methods of inhibiting cerebral amyloid angiopathy. The invention further provides methods of treating a disease state characterized by cerebral amyloid angiopathy in a subject with an A&bgr;40 inhibitor having the structure:
Q-[—SO3−X+]n or Q-[—OSO3−X+]n
wherein Q is a carrier group; X+ is a cationic group; and n is one.
Abstract: Methods and compositions which are useful in the treatment of amyloidosis. In particular, methods and compositions are provided for inhibiting, preventing and treating amyloid deposition, e.g., in pancreatic islets, wherein the amyloidotic deposits are islet amyloid polypeptide (IAPP)-associated amyloid deposition or deposits. The methods of the invention involve administering to a subject a therapeutic compound which inhibits IAPP-associated amyloid deposits. Accordingly, the compositions and methods of the invention are useful for inhibiting IAPP-associated amyloidosis in disorders in which such amyloid deposition occurs, such as diabetes.
Type:
Grant
Filed:
May 23, 2000
Date of Patent:
May 13, 2003
Assignee:
Queen's University of Kingston
Inventors:
Walter A. Szarek, Donald F. Weaver, Xianqi Kong, Ajay Gupta, David Migneault
Abstract: Therapeutic compounds and methods for modulating amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is modulated by the administration to a subject of an effective amount of a therapeutic compound comprising a phosphonate group and a carboxylate group, a congener thereof, or a pharmaceutically acceptable salt or ester thereof. In preferred embodiments, an interaction between an amyloidogenic protein and a basement membrane constituent is modulated.
Type:
Grant
Filed:
May 17, 2001
Date of Patent:
August 27, 2002
Assignee:
Queen's University at Kingston
Inventors:
Walter A. Szarek, Xianqi Kong, Gregory R. J. Thatcher, Boris Gorine